PHARMACYCLICS INC 4
4 · PHARMACYCLICS INC · Filed May 28, 2015
Insider Transaction Report
Form 4
Tan Heow
SVP Global Mfg & Technical Ops
Transactions
- Disposition to Issuer
Common Stock (Right to Buy)
2015-05-26−67,912→ 0 totalExercise: $27.05Exp: 2022-05-07→ Common Stock (67,912 underlying) - Disposition from Tender
Common Stock
2015-05-26$261.25/sh−11,721$3,062,111→ 0 total - Disposition to Issuer
Common Stock (Right to Buy)
2015-05-26−50,000→ 0 totalExercise: $61.60Exp: 2022-10-26→ Common Stock (50,000 underlying) - Disposition to Issuer
Common Stock (Right to Buy)
2015-05-26−30,000→ 0 totalExercise: $102.22Exp: 2024-04-02→ Common Stock (30,000 underlying)
Footnotes (3)
- [F1]Includes 259 shares acquired under the Pharmacyclics, Inc. Employee Stock Purchase Plan on April 30, 2015.
- [F2]Price reflects aggregate per share consideration paid pursuant to the Tender Offer.
- [F3]Pursuant to terms of the Agreement and Plan of Reorganization (the "Merger Agreement") dated March 4, 2015, by and between the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Oxford Amherst Corporation, a Delaware corporation and a direct wholly owned subsidiary of AbbVie and Oxford Amherst LLC, a Delaware limited liability company and a direct wholly owned subsidiary of AbbVie this option was cancelled in exchange for a cash payment equal to the number of shares subject to the option multiplied by the difference between $261.25 and the exercise price of the option, subject to applicable withholding taxes and pursuant to the procedures set forth in the Merger Agreement.